In response to favorable coverage from Wall Street, shares of Natera (NASDAQ: NTRA), a diagnostics company focused on noninvasive genetic testing, rose 18% as of 4 p.m. EDT on Monday.Natera's bulls can thank Morgan Stanley (NYSE: MS) and Canaccord Genuity for today's price action. Morgan Stanley published a bullish research note to investors on Monday that featured a price target increase on Natera's stock from $16 to $20.